Mayuresh Joshi of Angel Broking told CNBC-TV18, "In all likelihood I will buy Sun Pharma at current price. Clearly you saw the on and off that was going on, the warning letter contents of Sun Pharma, the Gleevec approval which has come through. So, lot more has happened for Sun Pharma and clearly the street is aware as I have been pointing out time and again that FY16 is going to be very soft as far as earnings are concerned. There are going be network integration costs with Ranbaxy that are going to play on the balance sheet.""In our opinion a lot has played out in terms of negative news probably on the stock. They have got a very strong Abbreviated New Drug Application (ANDA) pipeline and any approvals over the next few quarters are going to be incrementally positive. So, we maintain a positive view on the stock with a target of Rs 950 over the next 12-15 months," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
